Remove Bioinformatics Remove Contract Manufacturing Remove Licensing Remove Life Science
article thumbnail

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

In-Vivo 52